Identifying and targeting oncogenic fusion genes have revolutionized the treatment of leukemia, such as PML-RARα fusion gene in acute promyelocytic leukemia. Here we identified an intrachromosomal fusion gene located on chromosome 19q.13 between UBA2 and WTIP gene in a case of acute myeloid leukemia. The UBA2-WTIP fusion gene contains the N-terminal E1_enzyme_family, VAE_Ubl domains of UBA2, and the C-terminal LIM domains of WTIP. The UBA2-WTIP fusion was detected by reverse transcriptase polymerase chain reaction and Sanger sequencing in 19 of 56 acute myeloid leukemia samples (33.9%). Ectopic expression of the UBA2-WTIP fusion in human acute myeloid leukemia KG-1a cells showed enhanced cell proliferation both in vitro and in vivo. The UBA2-WTIP fusion induced phosphorylation of STAT3, STAT5 and ERK1/2, and abrogates WTIP-mediated mammalian processing body formation. Finally, triptolide displayed selective cytotoxicity against KG-1a cells harboring the UBA2-WTIP fusion. Collectively, our findings suggest that the UBA2-WTIP fusion is an oncogenic fusion gene, as well as a promising therapeutic target for the treatment of acute myeloid leukemia.
Introduction
Acute myeloid leukemia (AML), the most common hematological malignancy in adults, is a highly heterogenous disease characterized by sustained proliferation of myeloid stem/progenitor cells and subsequent bone marrow failure [1] [2] [3] [4] [5] [6] . Despite improvements in conventional chemotherapy and hematopoietic stem cell transplant (HSCT), the overall survival of AML is poor and the five-year survival rate is less than 50% [7] [8] [9] [10] .
It is encouraging that targeting oncogenic fusion genes have cured a portion of leukemia, such as acute promyelocytic leukemia (APL) harboring PML-RARα fusion as well as chronic myeloid leukemia harboring BCR-ABL1 fusion [11] [12] [13] [14] . A considerable number of fusion genes have been discovered in AML, which were largely responsible for disease pathogenesis. However, the pathogenic mechanisms of these fusion genes in AML have not been fully elucidated.
Here we used RNA sequencing to search for novel fusion genes in AML. We identified a fusion gene, the UBA2-WTIP fusion, from a relapsed AML patient with hyperleukocytosis and extramedullary infiltration. UBA2 and WTIP have opposite biological functions in tumorigenesis. UBA2 is a catalytic-subunit of SUMO-activating enzyme (SAE), which is involved in protein ubiquitination and cancer cell proliferation [15] . WTIP was first identified as the Wilm's tumor (WT1)-interacting protein in a yeast two-hybrid assay [16] . WTIP represses WT1-dependent gene expression and has potential tumor suppressor function [17] . Additionally, WTIP was also identified to localize to mammalian processing body (P-body), which is involved in microRNA (miRNA)-mediated gene silencing [18, 19] . Thereby, it is interesting to investigate the roles of the UBA2-WTIP fusion in AML.
In this study, we identified the UBA2-WTIP fusion in 19/56 AML patients (33.9%) by RT-PCR and Sanger sequencing. The functional study suggested that the UBA2-WTIP fusion promoted cell proliferation both in vitro and in vivo. Moreover, triptolide had selective cytotoxicity against human leukemia cells harboring the UBA2-WTIP fusion. Our findings demonstrate that the UBA2-WTIP fusion is an oncogenic fusion gene, as well as a promising therapeutic target in AML.
Material and methods

Clinical samples
Peripheral blood mononuclear cells (PBMCs) were obtained from AML patients and healthy donors with informed consent in accordance with the Declaration of Helsinki. All experiments were approved by the ethics committee of Second Affiliated Hospital, School of Medicine, Zhejiang University.
Cell culture
KG-1a cells (human acute myeloid leukemia cell line), HEK293 and 293 T cells were obtained from American Type Culture Collection (ATCC, USA). KG-1a cells was cultured in RPMI1640 medium containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin. HEK293 and 293 T cells were cultured in DMEM medium with 10% FBS and 1% penicillin/streptomycin.
RNA extraction, cDNA synthesis
Total RNA was isolated by TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized using PrimeScript II 1st Strand cDNA Synthesis Kit (Takara) according to the manufacturer's instructions.
RNA sequencing
RNA library was constructed by using TruSeq® RNA LT Sample Prep Kit v2 (Illumina) according to the manufacturer's instructions. Hiseq. 2500 platform was used to sequence according to the manufacturer's instructions (Illumina). The RNA-Seq data was analyzed by the SOAPfuse project to predict fusion transcripts, as previously described [20].
Identification of full-length UBA2-WTIP fusion
The full-length UBA2-WTIP fusion transcript was amplified by using primers 5′-ATGGCACTGTCGCGGGGGCT-3′ and 5′-TCAGAGCTCAGTG ACGTGCA-3′. RT-PCR was performed using PrimeSTAR GXL DNA Polymerase (Takara) according to the manufacturer's instructions. The PCR fragments were confirmed by Sanger sequencing.
Analysis of UBA2-WTIP genomic structure
Total cellular DNA was isolated using the TaKaRa MiniBEST Universal Genomic DNA Extraction Kit (Takara) according to the manufacturer's instructions. Genomic DNA was amplified by using primers 5′-TGAAGACCTAGGAAAGGACGTTGAA-3′ and 5′-CACACGAG TCGCAGGTGAAGCAGTC-3′. The PCR fragments were confirmed by Sanger sequencing.
Detection of the UBA2-WTIP fusion transcript in AML patients
The UBA2-WTIP fusion transcript was amplified by using the primers 5′-TAGAAATGGCAGCCGGCTTC-3′ and 5′-CAGGAAGTCCTCC TGGCAGT-3′. The PCR fragments were confirmed by Sanger sequencing.
Construction of WTIP and UBA2-WTIP expression vectors
The WTIP coding sequence or UBA2-WTIP coding sequence with a FLAG-tagged sequence were cloned into the pLVX-tre3G vector (Clontech) using Hieff Clone™ One Step Cloning Kit (Yeasen). The pLVX-tre3G vector is a doxycycline-inducible system with a puromysin resistant gene.
Lentiviral infection
Lentiviral infection was carried out according to the manufacturer's instructions, as previously described [21] . Recombinant lentiviral particles were produced from 293 T cells. In brief, expressing construct vectors (9 μg) with viral packaging vectors psPAX2 (6 μg) and pMD2. G (3 μg) (Addgene) were co-transfected into 293 T cells (plated in the 100-mm 2 dish) using Polyjet transfection reagent (SignaGen) according to the manufacturer's instructions. The supernatant containing virus particles was collected and filtered 72 h after transfection, concentrated by ultracentrifugation at 4000 g for 15 min, and suspended in cell growth medium. KG-1a cells were infected with the UBA2-WTIP fusion or WTIP or empty viral particles. Cells were selected 48 h after infection by 2 μg/ml puromycin. Single colonies were cultured and propagated, and western blot was used to detect UBA2-WTIP or WTIP proteins.
MTT assay
KG-1a cells transfected with a construct expressing the UBA2-WTIP fusion, the wild-type WTIP, or control vector were cultured in 96-wells plates (500 cells/well) in the presence of doxycycline (Dox, 2 mg/ml) for indicated times, and cell proliferation was assessed by MTT assay.
Colony formation assay
KG-1a cells transfected with expressing vectors were cultured in a 6-wells plates (50 cells/well) using RPMI 1640 medium with 10% FBS and Dox (2 mg/ml) at 37 ℃ in a 95% air, 5% CO 2 humidified incubator for 14 days. Three wells of cell colonies were scored (≥50 cells).
In vivo tumor xenograft study
KG-1a cells transfected with expressing vectors were injected subcutaneously (1 ×10 7 cells) into NOD/SCID mice. Mice were sacrificed 5 weeks after injection, and tumors were isolated. Tumor volume (V) was calculated by using the formula (LXSXS)× 0.5 [22] , where L and S were the long and short dimensions, respectively. Animal experiments were approved by the ethics committee of the Second Affiliated Hospital, College of Medicine, Zhejiang University.
Confocal microscopy
HEK293 and KG-1a cells transfected with the UBA2-WTIP fusion or the wild-type WTIP were labeled with immunofluorescence-tagged antibodies. The primary antibody used was Anti-Flag M2 antibody (sigma, 1:200). The secondary antibody was anti-mouse AlexaFluor-488(Yeasen, 1:500). Cell nuclei were stained with DAPI (Sigma). Pbody was observed using Zeiss Confocal Laser Scanning Microscope 710 (Carl Zeiss MicroImaging GmbH).
Western blot analysis
Western blot was performed as previously described [23] . Antibodies were used at the following dilutions: phospho STAT3 Ser727 (Cell Signaling Technology, 1:1000), STAT3 (Cell Signaling Technology, 1:1000), phospho STAT5 Tyr694 (Cell Signaling Technology, 1:1000), STAT5 (Cell Signaling Technology, 1:1000), phospho ERK1/2 Thr202/Tyr204 (Cell Signaling Technology, 1:1000), ERK1/2(Cell Signaling Technology, 1:1000) and GAPDH (Proteintech,1:10000).
Statistical analysis
All data were expressed as means ± SD and were based on experiments performed at least in triplicate. Statistical significance was calculated by Student t-test. Survival analysis was calculated using the Kaplan-Meier method and compared by log-rank test. P < 0.05 was considered to be statistically significant.
Results
Identification of the UBA2-WTIP fusion gene
To identify novel fusion genes in AML, we carried out RNA sequencing (RNA-Seq) from a highly aggressive acute monocytic leukemia patient (patient 1). The fusion transcripts were subsequently analyzed from RNA-Seq data by SOAPfuse project. The RNA-Seq alignment revealed that exon 16 of the UBA2 gene fused to exon 2 of the WTIP gene on chromosome 19q13.11. The UBA2-WTIP fusion contains an N-terminal of UBA2 (comprising the E1_enzyme_family and the VAE_Ubl domains) and a C-terminal of WTIP containing three LIM domains, but lacks exon 1 of the WTIP gene, which contains a nuclear export sequence (NES) and a SH3 binding domain (Fig. 1A,  Supplementary Fig. S1 ). To validate the UBA2-WTIP fusion, we amplified the full-length UBA2-WTIP fusion transcript from this patient using RT-PCR (Fig. 1B and C) . Subsequent Sanger sequencing revealed that the PCR fragment contained exons 1-16 of the UBA2 gene and exons 2-8 of the WTIP gene.
Detection of the UBA2-WTIP fusion transcript in AML patients
To estimate the frequency of the UBA2-WTIP fusion in AML patients, we collected a cohort of 56 clinical AML patients before chemotherapy (Supplementary Table S1 ). We designed primers and examined peripheral blood specimens from these 56 AML patients (case 1-56) via RT-PCR and Sanger sequencing. The UBA2-WTIP fusion transcript was detected in 19 of 56 clinical AML patients (33.9%) (Fig. 2A) . However, the UBA2-WTIP fusion transcript was not detected in peripheral blood specimens from healthy donors ( Supplementary Fig.  S2 , Supplementary Table S2) .
Subsequently, we analyzed the white blood cell (WBC) count in these clinical AML patients. The UBA2-WTIP-positive patients had a significantly higher WBC count (92.5 ×10 9 /L) as compared with UBA2-WTIP-negative patients (17.0 ×10 9 /L) ( Fig. 2B) , suggesting that the UBA2-WTIP fusion gene is correlated with leukemia cell proliferation in AML patients. Moreover, we found that the median survival time was 10.5 months in the positive group, while the median survival time was 16.6 months in the negative group. The UBA2-WTIP fusion positive AML patients had significantly reduced overall survival as compared to the UBA2-WTIP fusion negative patients (P < 0.05) (Fig. 2C ). These results demonstrate that AML patients harboring the UBA2-WTIP fusion have a poor prognosis.
Analysis of genomic structure of the UBA2-WTIP fusion
Subsequently, we extracted genomic DNA from patient 1 and 10 other AML patients (case 1-10) to identify the exact breakpoints in genomic DNA (Fig. 3A) . We amplified a 239 bp genomic DNA fragment in 4/11 genomic samples via PCR (Fig. 3B, C) . Sanger sequencing revealed that the PCR fragment contained exon 16 of UBA2 and exon 2 of WTIP ( Supplementary Fig. S3 ). These results suggest that the UBA2-WTIP fusion gene is a direct fusion between exon 16 of UBA2 and exon 2 of WTIP. Colony formation assay showed that expression of UBA2-WTIP fusion increased colony numbers, while WTIP decreased colony numbers. Each experiment was repeated three times, and the results were expressed as mean ± standard deviation. (C) Expression of the UBA2-WTIP fusion promoted tumor growth in vivo. (** P < 0.01; *** P < 0.001).
Fig. 5. UBA2-WTIP activates STAT and ERK signaling, abrogates WTIP localizing to processing body (P-body). (A) Expression of the UBA2-WTIP fusion enhanced the phosphorylation of STAT3, STAT5 and ERK1/2. (B)
Immunofluorescence staining showed that P-bodies were abundantly present in the wild-type WTIP-expressing HEK293 cells and KG-1a cells (white arrows), however, P-bodies were diminished in the UBA2-WTIP-expressing HEK293 and KG-1a cells. 
The UBA2-WTIP fusion promotes leukemia cell proliferation both in vitro and in vivo
To explore the roles of the UBA2-WTIP fusion in leukemia cells, the UBA2-WTIP fusion or the wild-type WTIP was ectopically overexpressed respectively in human leukemia KG-1a cells. MTT assays were conducted to assess cell proliferation at indicated time points. The UBA2-WTIP-expressing cells proliferated faster compared with control cells (cells transfected with empty vectors) and the wild-type WTIPexpressing cells at day 7 (P < 0.001), while the wild-type WTIP-expressing cells proliferated approximately 50% less than the control cells (Fig. 4A) . Moreover, colony formation assay also showed that the UBA2-WTIP fusion induced a significant increase in the number of colonies, while the wild-type WTIP induced a significant decrease in the number of colonies (Fig. 4B) . These results suggest that the UBA2-WTIP fusion greatly enhanced the proliferation of leukemia cells, while the wild-type WTIP suppressed leukemia cell proliferation in vitro.
To determine whether the UBA2-WTIP fusion contributes to cell growth in vivo, KG-1a cells transfected with the UBA2-WTIP fusion, the wild-type WTIP or empty vectors were subcutaneously injected into NOD/SCID mice to establish xenograft tumors. NOD/SCID mice were treated daily with doxycycline (10 mg/ml) by oral gavage for 200 μl, and tumor volumes were measured every 7 days for 5 weeks. As shown in Fig. 4C , the UBA2-WTIP fusion tumors showed increases in tumor size, while the wild-type WTIP tumors showed decreases in tumor size at week 5. These results suggest that the UBA2-WTIP fusion promotes tumor growth, while WTIP suppress tumor growth in mice xenograft model.
The UBA2-WTIP fusion enhances phosphorylation of STAT3, STAT5 and ERK1/2
Deregulated STAT and ERK1/2 signaling promote cell proliferation and survival in leukemia cells [24] . Therefore, to investigate the molecular mechanisms of the UBA2-WTIP fusion on cell growth, we ectopically overexpressed the UBA2-WTIP fusion and detected the phosphorylation of STAT3, STAT5 and ERK1/2 by western blot. As shown in Fig. 5A , ectopic overexpression of the UBA2-WTIP fusion induced increase in phosphorylation of STAT3, STAT5 and ERK1/2 compared to control cells, suggesting that the UBA2-WTIP fusion activates the downstream oncogenic pathways.
The UBA2-WTIP fusion abrogates WTIP-mediated processing body (Pbody) formation
Previous studies reported that WTIP was a critical component of mammalian P-body, which is involved in miRNA-mediated gene silencing [18, 19] . To identify the roles of the UBA2-WTIP fusion on P-body formation, P-body was detected in HEK293 and KG-1a cells transfected with the UBA2-WTIP fusion or the wild-type WTIP. As expected, Pbodies were abundantly located in cytoplasm both in the wild-type WTIP-expressing HEK293 cells and KG-1a cells (Fig. 5B, white arrows) . However, P-bodies almost disappeared in UBA2-WTIP-expressing HEK293 and KG-1a cells (Fig. 5B) . These results indicate that the UBA2-WTIP fusion abrogates WTIP-mediated P-body formation.
The UBA2-WTIP fusion is a potential therapeutic target
Triptolide, a small molecule isolated from the herb Tripterygium wilfordii, has been shown to have antitumor effects by inhibiting growth and inducing apoptosis in various human leukemia cells [25, 26] . Here we demonstrated that triptolide displayed selective cytotoxicity against KG-1a cells transfected with the UBA2-WTIP fusion compared with cells transfected with empty vectors (Fig. 6A) . The IC 50 of the control cells was approximately two times higher than the UBA2-WTIP fusion (Fig. 6B) , which indicated that triptolide had selective cytotoxicity to KG-1a cells harboring the UBA2-WTIP fusion. Furthermore, western blot analysis revealed that the UBA2-WTIP fusion protein was significantly reduced in response to triptolide treatment after 48 h in a concentration-dependent manner (Fig. 6C) . These results suggest that the UBA2-WTIP fusion is a potential therapeutic target in AML.
Discussion
In this study, we identified the UBA2-WTIP fusion in 19 of 56 (33.9%) AML patients and mapped the exact position of breakpoints in the genomic DNA. Our results indicate that a high frequency of the UBA2-WTIP fusion is positively correlated with leukocytosis in clinical AML patients. Ectopic overexpression of the UBA2-WTIP fusion enhanced proliferation of leukemia cells both in vitro and in vivo, due to activation of downstream oncogenic pathways and abrogation of the wild-type WTIP gene function. Furthermore, triptolide had selectively cytotoxicity against leukemia cells harboring the UBA2-WTIP fusion.
Our results showed that the UBA2-WTIP fusion is a high frequency fusion gene in AML patients, which indicates the fusion gene may play important roles in leukemogenesis. A high white blood cell (WBC) count or leukocytosis was considered as a negative prognostic factor in AML [27] [28] [29] . The mean WBC count was significantly higher in the UBA2-WTIP fusion positive AML patients as compared to the UBA2-WTIP fusion negative patients. Moreover, AML patients harboring the UBA2-WTIP fusion had significantly shorter overall survival time. These data suggest that the UBA2-WTIP fusion is positively correlated with leukemia cell proliferation and is a potential prognostic factor in AML.
The UBA2-WTIP was negative in healthy donors in our study. However, in a previous study, Greger et al. reported the discovery of UBA2-WTIP fusion in healthy people at a rate of 9.1% (42/462) [30] . The discrepancy between these results may be due to different methods were used. We detected the UBA2-WTIP fusion in 19 of 56 (33.9%) AML patients by RT-PCR and RNA sequencing. When we applied the same methods to 43 healthy people, the results showed that none of them harboring this fusion gene. In their study, Greger et al. used a pipeline based on FusionMap software to search for fusion genes in RNA sequencing data from five different populations [30] . However, they didn't verify this fusion transcript by RT-PCR and RNA sequencing.
Rodriguez-Martin et al. reported that the UBA2-WTIP fusion protein had an altered SUMOylation activity due to the WTIP's high-affinity binding LIM domains [31] . However, the exact mechanism underlying the altered SUMOylation activity is still unclear. Here we provide novel mechanistic insight into the oncogenic mechanism of the UBA2-WTIP fusion. Our results demonstrated that the UBA2-WTIP fusion gene promoted proliferation of leukemia cells both in vitro and in vivo. Additionally, the UBA2-WTIP fusion induced constitutive phosphorylation of STAT3, STAT5 and ERK1/2. It is shown that STAT3, STAT5 and ERK1/2 proteins are critical oncogenic transcription factors of the JAK/ STAT and MAPK/ERK pathway, and deregulated STAT3, STAT5 or ERK1/2 signaling promotes cell proliferation and survival [24, 32] . Thus, our results strongly suggest that the UBA2-WTIP fusion is a potential oncogenic gene by activating the STAT and ERK signaling in AML. Furthermore, we discovered that the UBA2-WTIP fusion disrupted the WTIP-mediated P-body formation, which was necessary for microRNA-mediated gene silencing [18, 19] .
Targeting oncogenic fusion genes such as PML-RARα and BCR-ABL have revolutionized the molecule-targeted treatment of leukemia [11] [12] [13] [14] . Triptolide, a small molecule isolated from the herb Tripterygium wilfordii, has been used for treatment of immune inflammatory diseases for decades [33] . Recently, triptolide has been shown to have antitumor activities by inhibiting growth and inducing apoptosis in a variety of human tumor cells [34, 35] . In human leukemia cells, triptolide inhibits cell growth and induces apoptosis through multiple mechanisms, including NF-κB inhibition, MAPKs activation, induction of caspase-dependent death, and JAK/STAT inhibition [25, 36, 37] . Here we demonstrated that triptolide displayed selective cytotoxicity against UBA2-WTIP-expressing KG-1a cells as compared with control cells. These data suggest that the UBA2-WTIP fusion gene is a potential molecular target for therapeutic strategy of AML.
In conclusion, our findings demonstrate that, in leukemia cells, ectopically overexpressing the UBA2-WTIP fusion promotes leukemia cell growth both in vitro and in vivo. By inducing phosphorylation of STAT3, STAT5, ERK1/2 and abrogating WTIP-mediated P-body formation, the UBA2-WTIP fusion has an oncogenic ability in leukemia. Furthermore, the UBA2-WTIP fusion is positively correlative to leukocytosis in clinic, as well as a promising target to improve therapeutic effects of AML.
